SID.ir New Version

Use Online Translation Powered By

Click Here STRS

STRS

Paper Information
Journal:   IRANIAN JOURNAL OF BASIC MEDICAL SCIENCES   JULY 2014 , Volume 17 , Number 7; Page(s) 509 To 515.
 
Paper: 

Effect Of Oral Genistein Administration In Early And Late Phases Of Allergic Encephalomyelitis
 
 
Author(s):  Razeghi Jahromi Soodeh, Arrefhosseini Seyed Rafi, Ghaemi Amir, Alizadeh Akram, Sabetghadam Fateme, Toghae Mansoureh*
 
* NEUROLOGY WARD, SINA HOSPITAL, EMAM KHOMEINI STREET, TEHRAN, IRAN
 
Abstract: 
Objective (s): Experimental allergic encephalomyelitis (EAE) is an autoimmune disease validated as animal model of multiple sclerosis (MS). Administration of genistein, a phytoestrogenic component of soy, to mice at the onset of EAE is known to attenuate the clinical signs of the disease. The potential effects of genistein on established EAE is less studied. In the current study, we aimed to compare the effects of genistein administration on EAE severity in early and late phases of the disease.Materials and Methods: The C57BL/6 mice were induced with EAE, using MOG 35-55 and gavaged with genistein (300 mg/kg) either after the appearance of the first clinical sign or 30 days post disease induction for ten days.24 hr after the last gavage, mice were sacrificed. Brains and spleens were removed for assessing lymphocyte proliferation, cell cytotoxicity, and cytokine profile. Spinal cords were dissected to assess the amount of demyelination using Luxol fast blue/cresyl violet staining.Results: Administering mice with genistein, after the establishment of EAE, did not reverse the clinical signs of disease. However, treating with genistein at the onset of disease alleviated the clinical signs by reducing neuronal demyelination. Genistein suppressed the production of IFN-g and enhanced IL-10 secretion in splenocyte and brain. Genistein also reduced IL-12 and TNF-a secretion in splenocytes, suppressed the proliferation of T-cells, and reduced the cell cytotoxicity.Conclusion: Genistein oral therapy might only reduce EAE severity if started in early phases of the disease.
 
Keyword(s): EXPERIMENTAL ALLERGIC, ENCEPHALOMYELITIS (EAE), GENISTEIN, IMMUNOMODULATION, INTERFERON-GAMMA, MULTIPLE SCLEROSIS
 
 
International related papers: 
 
Most related Highly related Moderately related Least related
 
References: 
  • Not Registered.
  •  
  •  
 
Citations: 
  • Not Registered.
 
+ Click to Cite.
APA: Copy

RAZEGHI JAHROMI, S., & ARREFHOSSEINI, S., & GHAEMI, A., & ALIZADEH, A., & SABETGHADAM, F., & TOGHAE, M. (2014). EFFECT OF ORAL GENISTEIN ADMINISTRATION IN EARLY AND LATE PHASES OF ALLERGIC ENCEPHALOMYELITIS. IRANIAN JOURNAL OF BASIC MEDICAL SCIENCES, 17(7), 509-515. https://www.sid.ir/en/journal/ViewPaper.aspx?id=405381



Vancouver: Copy

RAZEGHI JAHROMI SOODEH, ARREFHOSSEINI SEYED RAFI, GHAEMI AMIR, ALIZADEH AKRAM, SABETGHADAM FATEME, TOGHAE MANSOUREH. EFFECT OF ORAL GENISTEIN ADMINISTRATION IN EARLY AND LATE PHASES OF ALLERGIC ENCEPHALOMYELITIS. IRANIAN JOURNAL OF BASIC MEDICAL SCIENCES. 2014 [cited 2022August14];17(7):509-515. Available from: https://www.sid.ir/en/journal/ViewPaper.aspx?id=405381



IEEE: Copy

RAZEGHI JAHROMI, S., ARREFHOSSEINI, S., GHAEMI, A., ALIZADEH, A., SABETGHADAM, F., TOGHAE, M., 2014. EFFECT OF ORAL GENISTEIN ADMINISTRATION IN EARLY AND LATE PHASES OF ALLERGIC ENCEPHALOMYELITIS. IRANIAN JOURNAL OF BASIC MEDICAL SCIENCES, [online] 17(7), pp.509-515. Available: https://www.sid.ir/en/journal/ViewPaper.aspx?id=405381.
 
  pdf-File
Yearly Visit 39
 
 
Latest on Blog
Enter SID Blog